

```
var drug_url = "elbasvir-grazoprevir";
```



Elbasvir-Grazoprevir (Zepatier)

- [Editor's Summary](#)
- [Prescribing Information](#)
- [Clinical Trials](#)
- [References](#)
- [Slide Deck](#)
- [Teaching Resources](#)

Table of Contents

- [Elbasvir-Grazoprevir Zepatier Editor's Summary](#)
- [Drug Summary](#)
- [Class and Mechanism](#)
- [Manufacturer for United States](#)
- [Cost and Medication Access](#)
- [Adverse Effects](#)
- [Key Drug Interactions](#)

Drug Summary

Elbasvir-grazoprevir provides a safe, effective, well-tolerated, one-pill once-daily option for the treatment-naïve and treatment-experienced patients with genotype 1 or 4 infection. Patients with genotype 1a will need resistance testing prior to initiation of therapy. The presence of a substitution at amino acid positions 28, 30, 31, or 93 (seen in up to 10-15% of genotype 1a patients) requires the addition of ribavirin and extension of therapy from 12 to 16 weeks. Based on the C-SURFER data, this regimen is a particularly attractive option for patients with HCV and severe renal impairment (estimated Glomerular Filtration Rate [eGFR] less than 30 mL/min/1.73m²) for whom sofosbuvir-based regimens may not be optimal. The wholesale acquisition cost for elbasvir-grazoprevir (\$54,600) is notably lower than other first-line regimens.

Class and Mechanism

Elbasvir-grazoprevir (*Zepatier*) ([Figure 1](#)) is an oral fixed-dose combination of an NS5A replication complex inhibitor (elbasvir), and a “later”-generation HCV NS3/4A protease inhibitor (grazoprevir). Elbasvir (formerly MK-8742) is a small-molecule inhibitor of nonstructural protein 5A and possesses in vitro activity against most major HCV genotypes and some viral variants resistant to earlier NS5A inhibitors. Grazoprevir (formerly MK-5172) is a macrocyclic compound that reversibly binds to the

HCV NS3/4A protease, an enzyme responsible for cleaving and processing the HCV-encoded polyprotein. It is distinct from earlier-generation protease inhibitors in its potent in vitro activity against a broader array of HCV genotypes, as well activity against some of the major resistance-associated variants (R155K and D168Y) resulting from failure with a first-generation protease inhibitors.

Manufacturer for United States

The fixed-dose combination medication elbasvir and grazoprevir (*Zepatier*) is manufactured by Merck & Co., Inc.

Cost and Medication Access

Merck has established a list price of \$54,600 for a 12-week treatment course. For patients needing a 16-week course, the list price is \$72,800.

- Merck has an active Patient Assistance Program for patients who cannot obtain or afford elbasvir-grazoprevir. Information on the program can be obtained at Merck Patient Assistance Program ([Merck Helps](#)) website or by calling 1-800-405-5810.
 - Merck has also developed a co-pay assistance program. There are specific conditions that apply. Information to help patients get access and support to elbasvir-grazoprevir is available on the [Merck Access and Support Services](#) website.
-

Adverse Effects

Using pooled data from phase 2 and 3 trials (N=834), the most common adverse observed in patients receiving elbasvir-grazoprevir were fatigue (11%), headache (10%), and nausea (5%). Elevations in alanine aminotransferase levels (ALT) to greater than 5 times the upper limit of normal occurred in 1% of subjects, typically occurring at or after 8 weeks of therapy, with most resolving at or after the completion of therapy. To date, the rash and photosensitivity noted with earlier protease inhibitors has not been a problem in patients receiving elbasvir-grazoprevir.

Key Drug Interactions

For complete information on elbasvir-grazoprevir-related drug interactions, see the [Drug Interactions section in the Elbasvir-Grazoprevir \(Zepatier\) Prescribing Information](#).

with elbasvir plus grazoprevir (deferred treatment arm). At baseline, 58% of the patients in the study had a positive urine drug screen (for a substance other than an opioid agonist). Most of the patients (76%) had genotype 1 infection and 21% had cirrhosis. The SVR12 results were available only for the immediate treatment group and 95% of patients achieved an SVR12 (when excluding patients who discontinued the trial for non-treatment related reasons). The results were similar regardless of whether the baseline urine drug screen was positive. Adherence with medications was excellent, with 99% of patients taking at least 90% of the medication.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-EDGE Coinfection

In this prospective single-arm, open-label clinical trial, 218 patients with chronic hepatitis C genotype 1, 4, or 6 and HIV coinfection received the fixed-dose combination of elbasvir-grazoprevir once daily for 12 weeks. Nearly all (97%) patients were on antiretroviral therapy with HIV viral suppression and the median CD4 cell count was 568 cells/mm³; 86% had genotype 1a or 1b infection and 35 (16%) had compensated cirrhosis. The overall SVR12 rate was 96% by primary analysis, with the breakdown by genotype showing 96.5% for genotype 1a, 95.5% for genotype 1b and 96.4% for genotype 4. All cirrhotic patients achieved an SVR12. When patients who did not achieve an SVR12 due to treatment discontinuation or reinfection were excluded, the overall SVR12 rate was 97%.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-EDGE Treatment-Experienced

In this randomized, open-label, phase 3 trial, 420 patients with genotype 1, 4, or 6 hepatitis C infection and a history of treatment failure with peginterferon and ribavirin received elbasvir-grazoprevir (50/100 mg), with or without ribavirin, for 12 or 16 weeks. Among patients who received a 12-week regimen, the SVR12 rate was 94% for elbasvir-grazoprevir with ribavirin and 92% for elbasvir-grazoprevir without ribavirin. In the 16-week treatment arms, the SVR12 rate was 97% and 92% for elbasvir-grazoprevir, with and without ribavirin respectively. Notably, of the 12 patients with genotype 1a who experienced viral relapse, 10 had evidence of a baseline NS5A resistance-associated variant.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-EDGE Treatment-Naive

In this randomized phase 3 trial, the safety and efficacy of the fixed-dose combination of elbasvir-grazoprevir (50/100 mg) once daily was evaluated in treatment-naïve patients with genotype 1, 4, or 6 hepatitis C infection, with or without compensated cirrhosis. Investigators randomized (in a 3:1 ratio) 421 patients to immediate versus delayed treatment arms. In the latter group, patients received a placebo for 12 weeks, followed by a 4-week interval, followed by elbasvir-grazoprevir for 12 weeks. The overall SVR12 rate was 95%, with rates of 92% for genotype 1a, 99% for genotype 1b, 100% for genotype 4, and 80% for genotype 6. Among the 70 cirrhotic patients enrolled in the trial, 97% achieved an SVR12 with no statistically significant difference compared with non-cirrhotic patients.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-SALVAGE

In this open-label, single-arm, phase 2 trial, treatment-experienced patients with genotype 1 HCV and previous failure of peginterferon/ribavirin (PR) and an earlier-generation protease inhibitor (boceprevir, telaprevir, or simeprevir) were treated with elbasvir plus grazoprevir and ribavirin for 12 weeks. Patients with compensated cirrhosis were permitted and comprised 43% of the total 79 patients enrolled in the study. At 24 weeks post treatment, SVR occurred in 76 (96%) patients. There were 3 relapses (2 in genotype 1a and 1 in genotype 1b); all 3 relapsers had experienced virologic failure on a prior PI-based regimen and had NS3 variants detected at baseline.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-SCAPE

In this phase 2, open-label, randomized trial, investigators examined the safety and efficacy of different combinations of elbasvir plus grazoprevir, with or without ribavirin, for 12 weeks in patients with HCV genotype 2 and genotypes 4, 5, or 6 infection (with and without cirrhosis). Patients with genotype 2 infection were randomized to receive (a) elbasvir 50 mg plus grazoprevir 100 mg plus ribavirin or (b) grazoprevir 100 mg on its own with ribavirin. Patients with HCV genotype 4, 5, or 6 were randomized to receive elbasvir 50 mg plus grazoprevir 100 mg, with or without ribavirin. Among patients with genotype 2 infection, 80% achieved an SVR12 with the three drug-regimen of elbasvir plus grazoprevir plus ribavirin, whereas 73% did so with dual regimen of grazoprevir plus ribavirin. In subset analysis, patients with baseline HCV RNA less than or equal to 2 million IU/mL were more likely respond than those with viral levels greater than 2 million IU/mL. The SVR12 rates were 100%, 100%, and 90% for the 18 patients with genotype 4, 5, or 6 who received elbasvir plus grazoprevir plus ribavirin (72% for the 18 patients who did not receive ribavirin).

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-SURFER

In this phase 3, randomized study, investigators enrolled 224 patient with hepatitis C genotype 1 and chronic renal disease, including patients on hemodialysis, to receive immediate treatment with 12 weeks of therapy with elbasvir plus grazoprevir, or deferred therapy. Subjects in the deferred group received placebo during the first 12 weeks and use of placebo was considered important as a comparator for safety purposes, particularly due to safety concerns in this patient population with advanced renal disease. Overall, 80% of the patients enrolled in the trial were treatment-naïve and 76% were on hemodialysis. Among the 116 patients who completed therapy, 115 (99%) achieved an SVR12. Six patients were excluded from the modified full analysis set population, but all six had HCV RNA levels less than 15 IU/ml at that time of study discontinuation. The safety profile observed in patients who received grazoprevir plus elbasvir was comparable to that seen in patients receiving placebo.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-SWIFT

In this open-label phase 2 trial, investigators evaluated the efficacy of shorter durations (4, 6, or 8

weeks) of fixed-dose elbasvir-grazoprevir, given in combination with sofosbuvir, in treatment-naïve patients with HCV genotype 1 (n=102) or genotype 3 (n=41) infection, with and without compensated cirrhosis. Among the genotype 1 patients without cirrhosis who were treated with 6 weeks of therapy, 87% achieved an SVR12, compared with only 33% among those who had 4 weeks of therapy. Better SVR12 rates were obtained in cirrhotic patients with genotype 1 who had 8 weeks of treatment (94%) than with 6 weeks of therapy (80%). Non-cirrhotic patients with genotype 3 infection had excellent SVR12 rates (93% with 8 weeks of therapy and 100% with 12 weeks of therapy); for the cirrhotic patients, 91% achieved an SVR12 with 12 weeks of therapy.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-WORTHY

In this open-label, phase 2 trial involving patients with genotype 1 hepatitis C, treatment-naïve patients with compensated cirrhosis (cohort 1, n=123) and treatment-experienced patients with a prior null response to peginterferon plus ribavirin (cohort 2, n=130) were randomized to receive elbasvir plus grazoprevir, with or without ribavirin, for 12 or 18 weeks. In the cirrhotic cohort, 90% to 97% of patients achieved an SVR12; in the null responder cohort, SVR12 occurred in 91% to 100% of patients. The SVR12 rate for null cirrhotics (historically the most treatment refractory) was 94% for genotype 1a and 100% for genotype 1b. A subgroup analysis did not show a significant benefit of adding ribavirin to elbasvir plus grazoprevir.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

C-WORTHY Coinfection

This was a randomized, open-label, phase 2 trial of elbasvir plus grazoprevir, with or without ribavirin, in treatment-naïve HCV monoinfected patients without cirrhosis or patients with HIV and HCV coinfection without cirrhosis; the C-WORTHY Coinfection was a substudy conducted within a larger C-WORTHY study. In the monoinfected group 159 patients received different combinations of elbasvir plus grazoprevir that varied by elbasvir dose (20 or 50 mg), duration (8 or 12 weeks), and addition of ribavirin. In the HCV-HIV coinfection group, 59 patients were randomized to receive either elbasvir (50 mg) plus grazoprevir (100 mg), with or without ribavirin, for 12 weeks. In the HCV-monoinfected patient group, SVR12 was achieved in 80% of patients who received 8 weeks of therapy (with ribavirin), 93% with 12 weeks of therapy (with ribavirin), and 98% with 12 weeks of therapy (without ribavirin). For the HCV coinfecting patients, the SVR12 rates with 12 weeks of therapy were 97% (with ribavirin) and 87% (without ribavirin). These combinations were generally well-tolerated with fatigue, headache, and nausea the most common side effects.

View Clinical Trial: [In your Browser](#) | [Download PDF](#)

References

- Brown A, Hezode C, Zuckerman E, et al. C-SCAPE: efficacy and safety of 12 weeks of grazoprevir ± elbasvir ± ribavirin in patients with HCV GT2, 4, 5 or 6 infection. Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria; April 22-26, 2015. Abstract P0771.
- Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. *Clin Infect Dis.* 2016;62:32-6.
[[PubMed Abstract](#)]
- Carrion AF, Martin P. Safety and efficacy of elbasvir and grazoprevir for treatment of hepatitis C. *Expert Opin Drug Saf.* 2016;15:883-90.
[[PubMed Abstract](#)]
- Coburn CA, Meinke PT, Chang W, et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity. *ChemMedChem.* 2013;8:1930-40.
[[PubMed Abstract](#)]
- Dore GJ, Altice F, Litwin AH, et al. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. *Ann Intern Med.* 2016;165:625-634.
[[PubMed Abstract](#)]
- Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. *J Hepatol.* 2015;63:564-72.
[[PubMed Abstract](#)]
- Howe AY, Black S, Curry S, et al. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. *Clin Infect Dis.* 2014;59:1657-65.
[[PubMed Abstract](#)]
- Jacobson IM, Asante-Appiah E, Wong P, et al. Prevalence and Impact of Baseline NS5A Resistance-Associated Variants (RAVs) on the Efficacy of Elbasvir/Grazoprevir (EBR/GZR) Against GT1a Infection - 16 Weeks vs 12 weeks. Presented at the 66th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA. November 13-17, 2015.
- Jacobson IM, Lawitz E, Kwo PY, et al. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. *Gastroenterology.* 2017;152:1372-1382.e2.
[[PubMed Abstract](#)]
- Jacobson IM, Poordad F, Firpi-Morell R, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT). Presented at the 50th Annual Meeting of the European Association for the Study of the Liver, Vienna; April 22-26, 2015. Abstract O008.
[[PubMed Abstract](#)]
- Kwo P, Gane EJ, Peng CY, et al. Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection. *Gastroenterology.* 2017;152:164-175.e4.
[[PubMed Abstract](#)]
- Lagging M, Brown A, Mantry PS, et al. Grazoprevir plus peginterferon and ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection: a randomized trial. *J Viral Hepat.* 2015;23:80-8.
[[PubMed Abstract](#)]
- Lahser FC, Bystol K, Curry S, et al. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. *Antimicrob Agents Chemother.* 2016;60:2954-64.

- [\[PubMed Abstract\]](#)
- Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*. 2015;385:1075-86.
[\[PubMed Abstract\]](#)
 - Lawitz E, Poordad F, Gutierrez JA, et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. *Hepatology*. 2017;65:439-450.
[\[PubMed Abstract\]](#)
 - Manns MP, Vierling JM, Bacon BR, et al. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. *Gastroenterology*. 2014;147:366-76.e6.
[\[PubMed Abstract\]](#)
 - Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. *Lancet HIV*. 2015;2:e319-27.
[\[PubMed Abstract\]](#)
 - Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. *Lancet*. 2015;386:1537-45.
[\[PubMed Abstract\]](#)
 - Sulejmani N, Jafri SM, Gordon SC. Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. *Expert Opin Drug Metab Toxicol*. 2016;12:353-61.
[\[PubMed Abstract\]](#)
 - Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*. 2015;385:1087-97.
[\[PubMed Abstract\]](#)
 - Summa V, Ludmerer SW, McCauley JA, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. *Antimicrob Agents Chemother*. 2012;56:4161-7.
[\[PubMed Abstract\]](#)
 - Tong X, Kwong AD. Barrier to resistance: lessons from 2 direct-acting hepatitis C virus inhibitors, MK-5172 and Sofosbuvir. *Clin Infect Dis*. 2014;59:1675-7.
[\[PubMed Abstract\]](#)
 - Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. *Ann Intern Med*. 2015;163:1-13.
[\[PubMed Abstract\]](#)

Figures

Figure 1 Packaging - Elbasvir-Grazoprevir (Zepatier)

Photograph courtesy of Merck & Co., Inc.



Figure 2 Medication Contraindications

Source: Elbasvir-Grazoprevir (*Zepatier*) Prescribing Information

Drugs that are Contraindicated for Use with Elbasvir-Grazoprevir*	
Organic ion transporter polypeptide 1B (OATP1B) inhibitors	
Antimycobacterials	Rifampin
HIV medications	Atazanavir Darunavir Lopinavir Saquinavir Tipranavir
Immunosuppressants	Cyclosporine
Strong CYP3A Inducers	
Anticonvulsants	Phenytoin Carbamazepine
Herbal products	St. John's Wort (<i>Hypericum perforatum</i>)
HIV medications	Efavirenz [†]
*This is not a complete list of all drugs that inhibit OAT1B or strongly induce CYP3A †Efavirenz is listed as a strong CYP3A inducer because it reduced grazoprevir exposure by ≥80%	

Figure 3 Pill - Elbasvir-Grazoprevir (Zepatier)

Photograph courtesy of Merck & Co., Inc.

